Cargando…

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients

Mutational characterisation utilising plasma (PL)-derived circulating tumour DNA (ctDNA) in multiple myeloma (MM) has been recently described. Mutational analyses of paired bone marrow (BM) MM cell DNA and ctDNA from 76 patients (n = 24, new diagnosis (ND), n = 52, relapsed/refractory (RR)) for (ras...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mithraprabhu, Sridurga, Hocking, Jay, Ramachandran, Malarmathy, Choi, Kawa, Klarica, Daniela, Khong, Tiffany, Reynolds, John, Spencer, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678219/ https://www.ncbi.nlm.nih.gov/pubmed/31261969 http://dx.doi.org/10.3390/cancers11070917

Ejemplares similares

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients
por: Chen, Maoshan, et al.
Publicado: (2019)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma
por: Reale, Antonia, et al.
Publicado: (2021)

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2020)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma
por: Norton, Samuel E, et al.
Publicado: (2023)

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
por: Qiang, Wanting, et al.
Publicado: (2023)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Heavy menstrual bleeding and dysmenorrhea are improved by Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) of adenomyosis
por: Jayaram, Ramya, et al.
Publicado: (2016)

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
por: Kis, Olena, et al.
Publicado: (2017)

DNA Repair and Tumour Resistance
Publicado: (1974)

Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
por: Petrilla, Cole, et al.
Publicado: (2023)

The In Vitro Stability of Circulating Tumour DNA
por: Henao Diaz, Emanuela, et al.
Publicado: (2016)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
por: Board, Ruth E, et al.
Publicado: (2008)

Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

Circulating Tumour DNA in Melanoma—Clinic Ready?
por: Tivey, Ann, et al.
Publicado: (2022)

Circulating tumour DNA — looking beyond the blood
por: Tivey, Ann, et al.
Publicado: (2022)

Circulating tumour DNA in colorectal cancer management
por: Cohen, Ryan, et al.
Publicado: (2023)

The Role of DNA Repair in Genomic Instability of Multiple Myeloma
por: Ali, Jana Yasser Hafez, et al.
Publicado: (2022)

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
por: Sclafani, Francesco, et al.
Publicado: (2018)

Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients
por: Muendlein, Axel, et al.
Publicado: (2021)

Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags
por: Wee, Eugene J.H., et al.
Publicado: (2016)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

Sperm chromatin structure assay versus sperm chromatin dispersion kits: Technical repeatability and choice of assisted reproductive technology procedure
por: B, Vidya Laxme, et al.
Publicado: (2020)

Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker
por: Lam, Wai Kei Jacky, et al.
Publicado: (2019)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

High Fragmentation Characterizes Tumour-Derived Circulating DNA
por: Mouliere, Florent, et al.
Publicado: (2011)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Circulating Cell-Free Tumour DNA in the Management of Cancer
por: Francis, Glenn, et al.
Publicado: (2015)

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer
por: Tan, Melissa P., et al.
Publicado: (2018)

Landscape of circulating tumour DNA in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2020)

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
por: Loft, Matthew, et al.
Publicado: (2019)

Development of circulating tumour DNA analysis for gastrointestinal cancers
por: Nakamura, Yoshiaki, et al.
Publicado: (2020)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aoc6qoj1ribie9g4r1aji8n0po